Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Change in Receivables (2016 - 2025)

Editas Medicine (EDIT) has disclosed Change in Receivables for 11 consecutive years, with $7.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Receivables rose 6491.53% to $7.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $8.0 million, a 448.61% increase, with the full-year FY2024 number at $6.1 million, up 20.57% from a year prior.
  • Change in Receivables was $7.5 million for Q3 2025 at Editas Medicine, up from $78000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $16.1 million in Q4 2024 to a low of -$15.8 million in Q1 2025.
  • A 5-year average of $109578.9 and a median of -$1000.0 in 2024 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: plummeted 1133.33% in 2021, then surged 31306.25% in 2022.
  • Editas Medicine's Change in Receivables stood at $16000.0 in 2021, then soared by 31306.25% to $5.0 million in 2022, then soared by 54.53% to $7.8 million in 2023, then surged by 107.86% to $16.1 million in 2024, then plummeted by 53.27% to $7.5 million in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Change in Receivables are $7.5 million (Q3 2025), $78000.0 (Q2 2025), and -$15.8 million (Q1 2025).